Systemic Lupus Erythematosus Market to Register Incremental Growth During the Forecast Period | Key Companies – Xencor, Idorsia, Neovacs, Jansse, Merck, ILTOO, Biogen, Celgene, UCB Pharma, and Others

June 27 21:25 2022
Systemic Lupus Erythematosus Market to Register Incremental Growth During the Forecast Period | Key Companies - Xencor, Idorsia, Neovacs, Jansse, Merck, ILTOO, Biogen, Celgene, UCB Pharma, and Others
Delveinsight Business Research LLP
DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Systemic Lupus Erythematosus Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Systemic Lupus Erythematosus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Systemic Lupus Erythematosus: An Overview

According to the American College of Rheumatology “Systemic lupus erythematosus, ( SLE, Lupus) is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain.

Many patients experience fatigue, weight loss, and fever. Lupus flares vary from mild to severe. SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans.

The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria, however, SLE is difficult to diagnose in primary care because many of the symptoms (e.g., fatigue, rash, joint pain) are nonspecific and overlap with those of more common conditions. Furthermore, biomarkers are often negative or normal, early in the course of the illness. The most common presenting symptoms are constitutional, such as fatigue, weight loss, and fever without a focal infection, occurring in up to 90% of patients.

Systemic Lupus Erythematosus Market Key Facts

  • As per DelveInsight estimates, the total diagnosed prevalent cases of Systemic Lupus Erythematosus in the 7MM was found to be 484,200+ cases in 2017. Among all the countries, the estimates show a higher population of Systemic Lupus Erythematosus in the United States with 259,400+ cases in 2017.

  • Among the EU5 countries, the UK had the highest diagnosed prevalent population of Systemic Lupus Erythematosus with 62,800+ cases, followed by Italy in 2017. On the other hand, Spain had the lowest prevalent population.

  • Females are more prone to SLE than males in all 7MM countries.

Systemic Lupus Erythematosus Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Systemic Lupus Erythematosus market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Systemic Lupus Erythematosus market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), and competition with other therapies, brand value, and their impact on the market.

Systemic Lupus Erythematosus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Systemic Lupus Erythematosus Epidemiology Subtype Segmentation

  • Total Diagnosed Prevalent cases of Systemic Lupus Erythematosus

  • Gender-Specific cases of Systemic Lupus Erythematosus

  • Severity-Specific cases of Systemic Lupus Erythematosus

  • Treatable cases of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Lupus Erythematosus market or expected to get launched during the study period. The analysis covers Systemic Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Systemic Lupus Erythematosus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Systemic Lupus Erythematosus Therapeutics Analysis

The Systemic Lupus Erythematosus market dynamics is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period.

Some of the key companies in the Systemic Lupus Erythematosus Market include:

  • AstraZeneca

  • ImmuPharma

  • Eli Lilly

  • Janssen Pharmaceutical

  • Merck KGaA

  • ILTOO Pharma

  • Biogen

  • Celgene

  • UCB Pharma/Biogen

  • Neovacs

  • Idorsia Pharmaceuticals

  • Kezar Life Sciences

  • Bristol-Myers Squibb

  • Xencor

And others

Systemic Lupus Erythematosus Therapies covered in the report include:

  • Anifrolumab 

  • Lupuzor 

  • Baricitinib 

  • Stelara 

  • Atacicept

  • XmAb5871 

  • Lulizumab pegol 

  • Cenerimod 

  •  IFNα Kinoid

  • Dapirolizumab pegol 

  • CC-220

  • BIIB059 

  • ILT-101

  • KZR-616

And many more.


Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Systemic Lupus Erythematosus Competitive Intelligence Analysis

4. Systemic Lupus Erythematosus Market Overview at a Glance

5. Systemic Lupus Erythematosus Disease Background and Overview

6. Systemic Lupus Erythematosus Patient Journey

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Systemic Lupus Erythematosus Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Lupus Erythematosus Unmet Needs

10. Key Endpoints of Systemic Lupus Erythematosus Treatment

11. Systemic Lupus Erythematosus Marketed Products

12. Systemic Lupus Erythematosus Emerging Therapies

13. Systemic Lupus Erythematosus Seven Major Market Analysis

14. Attribute Analysis

15. Systemic Lupus Erythematosus Market Outlook (7 major markets)

16. Systemic Lupus Erythematosus Access and Reimbursement Overview

17. KOL Views on the Systemic Lupus Erythematosus Market.

18. Systemic Lupus Erythematosus Market Drivers

19. Systemic Lupus Erythematosus Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

US Healthcare Outlook Report
The US is the headquarters of several major pharmaceutical and medical device companies in the world. Due to this, the U.S. pharmaceutical market is the world’s most important national market. The US alone holds over 45 % of the global pharmaceutical market. Healthcare coverage in the US is provided through a combination of private health insurance and public health coverage. The two most important healthcare coverage plans in the US are Medicare and Medicaid.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States